Cooper (COO) Crashed 21% on a Fixable Inventory Reset While Record Cash Flow Piled Up

A company rarely announces record cash flow and watches a fifth of its market value evaporate in the same evening. That is roughly what happened to The Cooper Companies (COO) on September 9, when fiscal third-quarter results sent the stock down about 21% from the prior close and below its 52-week low. The earnings number beat Wall Street, and the quarter produced the largest free cash flow in the company's history. The tension in that sentence is the whole story: investors sold the top line and looked straight past the cash the contact-lens and fertility business is now throwing off.

Why the tape went red

The market's case is easy to state. Revenue of $1.066 billion came in about $30 million short of the roughly $1.1 billion analysts had expected, growing just ~1% on both a reported and an organic basis. CooperVision, the contact-lens engine that supplies roughly two-thirds of the company, was essentially flat for the quarter. Management then guided the current (fiscal fourth) quarter to just 0%–2% organic growth and cut its full-year revenue outlook. To a tape that had been treating Cooper as a growth stock, it looked as if the growth had stopped.

The detail that changed the picture is that the company hit pause on its own measuring stick. CooperVision spent the quarter deliberately shrinking how many lenses it shipped into U.S. distributors — a channel inventory reset born of private-label contract wins, consolidation, and distributors buying ahead of price increases. Management said the clean-up was about halfway done at quarter end and would be completed in this fiscal fourth quarter, which wraps up at the end of October. The demand underneath never broke: underlying U.S. consumption grew at a mid-single-digit rate, and Cooper's Americas segment would have grown about 5% without the destocking.

The tax number is noise, not the story

One of the quarter's headlines needs to be set aside before it misleads. GAAP earnings printed $2.24 per share, while adjusted earnings were $1.15 — a gap driven almost entirely by a discrete $307 million tax benefit from the favorable close of a U.K. tax examination over a 2021 intellectual-property transfer. That is an accounting catch-up, not operating profit, and it is the wrong reason to care about this stock. Strip it out and non-GAAP earnings rose a modest 4%, beating estimates for an 11th straight quarter. The durable piece is mildly encouraging — the resolution is expected to keep the company's non-GAAP tax rate lower for at least another ten years — but a one-time tax windfall is not the proof path. The cash flow is.

The cash-flow path says the opposite of the headline

Here is where the quarter stops looking like a broken growth story and starts looking like an expectations reset. Cooper generated $273 million of free cash flow in the quarter, up 66% year over year, from $341.7 million of operating cash flow after $68.7 million of capital spending. Year to date, free cash flow reached $528 million, up 86%. That FCF is a far bigger number than the top-line stall suggested, and it is why management could cut full-year revenue guidance and still hold full-year adjusted EPS guidance near $4.51–$4.55 — essentially where the year began — because the revenue hit is timing, not lost business.

The company has been telling investors to expect more than $2.2 billion of cumulative free cash flow across fiscal 2026 through 2028, on top of the ~$600 million to $625 million it lifted its full-year target to during this year. Against that raised FCF guide, the post-crash valuation is roughly a 5%–6% forward free-cash-flow yield — the kind of price a quality medical compounder with a shrinking share count rarely wears for long, provided the cash actually keeps coming.

Management is acting on that conviction rather than just talking about it. The company repurchased $339 million of stock during the quarter — and $445 million so far this fiscal year — then added another $1 billion to its buyback authorization, leaving roughly $1.5 billion of capacity. Buying back stock at a price that just fell to a fresh low is the most concrete statement a management team can make that it believes the hit is temporary.

What would prove this wrong

The whole case leans on one assumption: that CooperVision's demand is genuinely intact and will show up once the channel is clean. Management says that after the reset completes this quarter, CooperVision is positioned to grow back into the market's 4%–6% range in fiscal 2027. That is the proof point, and it is falsifiable. If, this time next year, CooperVision has not re-accelerated to that neighborhood, then the inventory story was partly a cover for real share loss — likely to low-cost daily disposables and a well-funded IUD competitor at CooperSurgical — and the thesis is broken. Cut without ego, and re-enter only if the numbers reset.

There are honest deductions against the cash story in the near term. Cooper guided current-quarter free cash flow to only about $170 million, before roughly $272 million of litigation payments tied to the CooperSurgical embryo-culture-media recall — a real cash drain that can flatten near-term reported FCF. And next year brings a scheduled step-up in the U.S. tax on foreign earnings, lifting the effective non-GAAP tax rate from about 15.5% to roughly 17.5% — a genuine headwind to 2027 earnings per share. On the strategic front, the board concluded its sale review of CooperSurgical and chose to keep it, pointing to shared services and what it called a "temporary disconnect" between the business's intrinsic value and the offers on the table. The market that wanted a value-unlocking sale did not get it.

What the next twelve months are about

The market is still pricing the old risk profile — a growth stock that just stopped growing — while the operating setup is already getting cleaner. Whether this is an opportunity comes down to a single, checkable question: does CooperVision return to mid-single-digit organic growth in fiscal 2027 after a channel clean-up that is scheduled to finish this quarter? The record free cash flow, the raised cash-flow target, and a management team using a beaten-down stock price to retire its own shares all say the bridge is there. The numbers have not broken; the expectation has. I can be wrong again — that is why the 2027 CooperVision growth rate, not the tax windfall and not the price target, is the thing to watch.